SOPHiA GENETICS (SOPH) Cash & Current Investments (2020 - 2026)

SOPHiA GENETICS has disclosed Cash & Current Investments across 7 years of filings, most recently posting $107.7 million for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 13.54% year-over-year to $107.7 million; the TTM figure through Jun 2026 stood at $107.7 million (up 13.54% YoY), while the FY2025 annual figure was $157.6 million, down 6.7% from the prior year.
• Cash & Current Investments came in at $107.7 million for Q2 2026 at SOPHiA GENETICS, up from $65.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $261.4 million in Q4 2023 to a low of $65.4 million in Q1 2026.
• Average Cash & Current Investments over 5 years is $143.4 million, with a median of $140.7 million recorded in 2023.
• Year-over-year, Cash & Current Investments jumped 237.75% in 2022 and sank 35.91% in 2024.
• Over 5 years, Cash & Current Investments stood at $178.6 million in 2022, then soared by 46.37% to $261.4 million in 2023, then sank by 35.4% to $168.9 million in 2024, then slipped by 6.7% to $157.6 million in 2025, then tumbled by 31.67% to $107.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $107.7 million in Q2 2026, $65.4 million in Q1 2026, and $157.6 million in Q4 2025.